Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis

Fernando Bessone, Natalia Poles, Marcelo G Roma

Abstract
Systemic lupus erythematosus (SLE) encompasses a broad spectrum of liver diseases. We propose here to classify them as follows: (1) immunological comorbidities (overlap syndromes); (2) non-immunological comorbidities associated to SLE; and (3) a putative liver damage induced by SLE itself, referred to as "lupus hepatitis". In the first group, liver injury can be ascribed to overlapping hepatopathies triggered by autoimmune mechanisms other than SLE occurring with higher incidence in the context of lupus (e.g., autoimmune hepatitis, primary biliary cirrhosis). The second group includes non-autoimmune liver diseases, such as steatosis, hepatitis C, hypercoagulation state-related liver lesions, hyperplasic parenchymal and vascular lesions, porphyria cutanea tarda, and drug-induced hepatotoxicity. Finally, the data in the literature to support the existence of a hepatic disease produced by SLE itself, or the occurrence of a SLE-associated prone condition that increases susceptibility to acquire other liver diseases, is critically discussed. The pathological mechanisms underlying each of these liver disorders are also reviewed. Despite the high heterogeneity in the literature regarding the prevalence of SLE-associated liver diseases and, in most cases, lack of histopathological evidence or clinical studies large enough to support their existence, it is becoming increasingly apparent that liver is an important target of SLE. Consequently, biochemical liver tests should be routinely carried out in SLE patients to discard liver disorders, particularly in those patients chronically exposed to potentially hepatotoxic drugs. Diagnosing liver disease in SLE patients is always challenging, and the systematization of the current information carried out in this review is expected to be of help both to attain a better understanding of pathogenesis and to build an appropriate work-up for diagnosis.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Systemic lupus erythematosus; Lupus hepatitis; Steatosis; Regenerative nodular hyperplasia; Hepatitis C; Autoimmune hepatitis; Hepatotoxicity; Nonsteroidal anti-inflammatory drugs; Methotrexate

Core tip: The existence of liver disease associated with lupus itself, or increased susceptibility to concomitant liver diseases, either autoimmune or non-autoimmune ones, is still somewhat controversial, and difficult to diagnose. Data in the literature are scarce, and often based on case reports or clinical studies with limited patient size or histological evidence. The pros and cons to support the existence of such pathological entities, and the still preliminary studies on the mechanisms involved, are critically discussed here. We concluded that liver is often a target of systemic lupus erythematosus, and biochemical liver tests should be systematically carried out in these patients.

Bessone F, Poles N, Roma MG. Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis

INTRODUCTION

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with variable clinical presentation, usually characterized by several immunological signs and symptoms\(^1\). It primarily affects women under 50 years of age, and is diagnosed on the basis of presence of at least 4 out of 11 criteria identified by the American College of Rheumatology (ACR), either sequentially or simultaneously, namely malar rash, discoid rash, photosensitivity, oral ulcers, nonerosive arthritis, pleuritis or pericarditis, renal disorders (proteinuria or cellular casts), neurologic disorder (seizures or psychosis), hematologic disorder (hemolytic anemia, leukopenia or thrombocytopenia) and immunologic disorders (anti-DNA, anti-Sm or antiphospholipid antibodies)\(^1\).

The most common symptoms are fever, weight loss, and a general lack of wellbeing and arthralgia, while the most frequent signs are skin rashes. Biochemical exams typically present anemia, and increased rates of erythrocytosis. Treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), corticoids, and immunomodulators. Death is generally caused by progressive renal insufficiency, severe impairment of the central nervous system, or multi-organic failure after systemic infection\(^1\).

Even though, as above mentioned, alterations of skin, joints and kidney, as well as of the cardiovascular, hematological and central nervous systems, are part of the criteria indicating morbidity, the liver can also be affected\(^1\). Although a true liver disease triggered by SLE itself is a controversial issue, 25% to 50% of patients may present alterations in the liver function tests (LFTs)\(^1\). The for and against data in the literature to support the existence of the multiple associations of SLE with liver disease will be discussed in detail in this review. Our literature inclusion criteria limited the citation of clinical cohort studies to those written in English language and published in peer reviewed journals; only very exceptional studies in other languages were included, when dealing with topics with extremely scarce information. The quotation studies in abstract form, when equivalent full papers were unavailable, was also very exceptional, and limited to peer reviewed, highly prestigious meetings.

PREVALENCE OF BIOCHEMICAL AND HISTOLOGICAL HEPATIC ALTERATIONS IN PATIENTS WITH SLE

Subclinical liver disease is common in SLE, and 25%-50% of patients with lupus may develop abnormal liver function at some point\(^1\). The more common laboratory abnormalities associated with the different kinds of liver disease related to lupus are summarized in Table 1. In addition, an overview of the main biochemical and histological findings reported in the literature is depicted in Table 2.

Hepatomegaly is detected in 12%-55% of SLE patients, depending on the analyzed series\(^7\). In an original article by Mackay et al\(^7\), the authors observed hepatomegaly and/or alterations in LFTs in 19 SLE patients, normal liver biopsies in 6 cases, and minimal histological changes in another 11 ones (fatty liver, portal fibrosis, and mild to moderate portal infiltrate). Histological changes compatible with chronic hepatitis with progression to cirrhosis were confirmed in the remaining 2 patients. Similar findings were obtained by Polish researchers in a study of 18 SLE patients; whereas 5 of them showed normal liver histologies, the other 13 ones showed only minimal hepatocellular changes\(^8\). These results do not agree with those observed by Runyon et al\(^13\) who, in a retrospective review of 238 patients with SLE, observed hepatomegaly in 39% of patients, splenomegaly in 6% and jaundice in 24%. Twenty one percent of patients were defined as carriers of liver disease based on abnormal liver histologies or, in some cases, elevation of liver enzymes 2 times over the upper limit of normal (ULN).

In the same study, liver histology of 33 patients showed steatosis (36%), cirrhosis and chronic active hepatitis (12%), hepatic granulomatosis, centrilobular necrosis (9%), and chronic hepatitis and microabscesses (6%). These findings were very challenging for the common view at the beginning of 80 s, and prompted other researchers to replicate these results. However, only one year after this report, Gibson et al\(^14\) failed to reproduce such a high rate of severe liver disease associated with SLE. They reported 55% of patients with increase in transaminase levels among 81 patients with SLE, and identified SLE as the only explanation for this abnormality in 29% of the cases. Histological analysis of 7 of these patients revealed portal inflammation in 5, fatty liver in 1, and active chronic hepatitis in the remaining one. They also reported a 23% increase in the levels of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) and alkaline phosphatase (ALP) (≤ 2 times ULN), with a notable predominance among patients that presented active clinical signs of SLE. All of these abnormalities normalized with steroid treatment.

A prospective analysis by Miller et al\(^15\) recruited 260 patients with SLE that were followed up for a 12-mo period. In the follow-up examinations, liver enzymes levels were high in 23% of them. Clinical liver disease was observed in only 29% of the cases, while causes for liver compromise unrelated to SLE were verified in only 15% of the cases. No specific cause for liver disease other than SLE could be identified in 8% of the patients. The histological analysis carried out on 14 patients found only minimal and non-specific changes. It is noteworthy that the increase in transaminase levels in 12 out of 15 patients appeared concomitantly with lupus activity.
A much lower frequency of liver abnormalities was reported by Fox et al.\cite{16} in a retrospective cohort of 200 patients, where an increase of liver enzymes was documented in only 2.5% of the cases. These biochemical changes were associated with liver clinic manifestations only in few cases, and had no relationship with plasmatic ribosomal-P antibodies.

Very interesting findings were published by Matsumoto et al.\cite{17}

### Table 1 Biochemical and histological liver abnormalities in SLE patients according to different reports in the literature

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Study type</th>
<th>Patients with SLE</th>
<th>NO. of patients with biochemical alterations and alteration types</th>
<th>Liver histological findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mackay et al\cite{11}</td>
<td>Retrospective</td>
<td>19 (n = 19)</td>
<td>↑ AST, ALT</td>
<td>Minimal changes, portal fibrosis, steatosis, inflammation (n = 11)</td>
</tr>
<tr>
<td>Chwaliszka-Sadowska et al\cite{12}</td>
<td>Retrospective</td>
<td>NA</td>
<td></td>
<td>Chronic hepatitis (n = 2)</td>
</tr>
<tr>
<td>Runyon et al\cite{13}</td>
<td>Retrospective</td>
<td>238 (n = 124)</td>
<td>↑ AST, ALT, total bilirubin, ALP, GGT, LDH (&gt; 2 × ULN)</td>
<td>Steatosis (n = 12) Others: cirrhosis, chronic hepatitis, granulomatosis, chronic hepatitis, steatosis, cholestasis, centrilobular necrosis (n = 33)</td>
</tr>
<tr>
<td>Gibson et al\cite{14}</td>
<td>Retrospective</td>
<td>81 (n = 64)</td>
<td>↑ AST, ALT, ALP</td>
<td>Portal inflammation (n = 5) Steatosis (n = 1) Chronic hepatitis (n = 1) Minimal changes (n = 14)</td>
</tr>
<tr>
<td>Miller et al\cite{15}</td>
<td>Prospective</td>
<td>260 (n = 84)</td>
<td>↑ AST, ALT, ALP</td>
<td>Hepatic arteritis (n = 11) Steatosis (n = 53) RNH (n = 5) Viral hepatitis (n = 2) SLE-PBC overlap syndrome (n = 1) SLE-AIH overlap syndrome (n = 1)</td>
</tr>
<tr>
<td>Chwalińska-Sadowska et al\cite{16}</td>
<td>Retrospective</td>
<td>73</td>
<td>NA</td>
<td>Steatosis (n = 53) RNH (n = 5) Viral hepatitis (n = 2) SLE-PBC overlap syndrome (n = 1) SLE-AIH overlap syndrome (n = 1)</td>
</tr>
<tr>
<td>Luangjaru et al\cite{9}</td>
<td>Retrospective</td>
<td>225 (n = 80)</td>
<td>↑ AST, ALT (≤ 4 × ULN)</td>
<td>NA</td>
</tr>
<tr>
<td>Chowdhary et al\cite{7}</td>
<td>Retrospective</td>
<td>192 (n = 40)</td>
<td>↑ AST, ALT</td>
<td>HCV (n = 3) Steatosis (n = 5) SLE-AIH overlap syndrome (n = 4) SLE-PBC overlap syndrome (n = 3) Cryptogenic cirrhosis (n = 1)</td>
</tr>
<tr>
<td>Piga et al\cite{3}</td>
<td>Retrospective</td>
<td>242 (n = 59)</td>
<td>↑ AST, ALT (≥ 2 × ULN)</td>
<td>NA</td>
</tr>
<tr>
<td>Her et al\cite{138}</td>
<td>Retrospective</td>
<td>141 (n = 46)</td>
<td>↑ Total bilirubin, AST, ALT, LDH, ALP (≥ 2 × ULN)</td>
<td>NA</td>
</tr>
<tr>
<td>Huang et al\cite{90}</td>
<td>Retrospective</td>
<td>1533 (n = 134)</td>
<td>↑ AST, ALT (≥ 2 × ULN) during 2 yr</td>
<td>Chronic Hepatitis (n = 6) Minimal changes (n = 4) Normal (n = 3) (n = 10)</td>
</tr>
<tr>
<td>Zheng et al\cite{2}</td>
<td>Retrospective</td>
<td>504 (n = 47)</td>
<td>↑ Total bilirubin (13%), ALT (98%), ALP (42%), GGT (49%)</td>
<td>Portal blood cell infiltration (n = 8) Hydropic degeneration (n = 8) Steatosis (n = 2) Mild cholestasis (n = 2) Focal necrosis (n = 1) Nodular cirrhosis (n = 1) Lupus hepatitis (n = 16): Unspecific reactive hepatitis (88%) Active hepatitis (12%) SLE-AIH overlap syndrome (n = 6): Interface hepatitis (100%): Cirrhosis (33%) SLE-PBC overlap syndrome (n = 3)</td>
</tr>
<tr>
<td>Takahashi et al\cite{18}</td>
<td>Prospective</td>
<td>206 (n = 123)</td>
<td>↑ AST, ALT (99%) ↑ ALP and GGT (81%)</td>
<td></td>
</tr>
</tbody>
</table>

SLE: Systemic lupus erythematosus; ULN: Upper limit of normal; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LDH: Lacto dehydrogenase; ALP: Alkaline phosphatase; GGT: Gamma glutamyl transferase; HCV: Hepatitis C virus; PBC: Primary biliary cirrhosis; AIH: Autoimmune hepatitis.
moto et al, who analyzed liver histology of 73 patients with SLE. They identified fatty liver as the major feature in 72% of the cases, while nodular regenerative hyperplasia, viral hepatitis, primary biliary cirrhosis (PBC), and autoimmune hepatitis (AIH) were identified as the main cause of liver disease only in few cases (6.8%, 4.1%, 2.7%, and 2.7%, respectively).

Finally, Takahashi et al reported recently that liver dysfunction was apparent in 123 (59.7%) out of 206 patients. They identified different causes of liver dysfunction as follows: induced by drug (30.9%), caused by SLE itself (28.5%), fatty liver (17.9%), AIH (4.9%), PBC (2.4%), cholangitis (1.6%), alcohol (1.6%), and viral hepatitis (0.8%). The liver dysfunction tends to be mild, except when caused by AIH.

From the studies reported above, it is readily apparent that the published data linking liver diseases with SLE during the last four decades are highly heterogeneous, and that a high number of cases lack adequate histological documentation.

**LIVER DISEASES IN THE SLE CONTEXT**

The frequent association between SLE and LFT alterations may be accounted for by three possibilities, namely: (1) the existence of some kind of liver parenchymal injury associated with SLE alone, often referred to as “lupus hepatitis”; (2) the occurrence of an overlap syndrome by which SLE shows additional features of another autoimmune liver disease; and (3) the concurrency of comorbidity of SLE with a non-autoimmune hepatopathy, e.g., drug-induced liver damage, viral hepatitis or thrombotic liver disease, among others.

**Lupus hepatitis**

Although it is still a controversial issue, there is compelling evidence in the literature that lupus itself is not associated with a specific, severe and progressive liver injury. However, several authors have pointed a role for SLE in triggering an often subclinical hepatopathy, referred to as “lupus hepatitis”. They described this disease as an asymptomatic hypertransaminasemia frequently associated with exacerbations of the lupus disease, which returns to normal values after corticosteroid therapy.

May be a part the confusion begun in the early 50’s when AIH was wrongly referred to as “lupoid hepatitis” [11]. Subsequent studies added more confusion when no serology was available to rule out overlapping chronic viral diseases [hepatitis C virus (HCV), hepatitis B virus (HBV), cytomegalovirus, etc.] in SLE patients with hypertransaminasemia.

In the early 80’s, Runyon et al reactivated the debate publishing a very controversial study describing both a “canalicular cholestasis” profile and SLE-related cirrhosis as diseases triggered by lupus itself. As mentioned before, the sample analyzed in this study consisted of 33 lupus patients presenting different types of liver damage that were documented by liver biopsy, namely steatosis, chronic hepatitis, hemochromatosis, granulomatose hepatitis, cholestasis and cirrhosis. Serological and virological markers to rule out hepatitis C did not exist at this time.

As was also stressed above, another condition that is needed to rule out among SLE patients with hypertransaminasemia is an overlap with AIH, which represents a separate disease from lupus, both because of its distinct pathogenic mechanism (specific organ) and its distinctive biochemical, serological, and histological characteristics that allow for a clear differentiation.

Hypergammaglobulinemia, autoantibodies [antinuclear antibody (ANA), antismooth muscle antibody (ASMA), anti-liver-kidney microsome antibodies], a histological profile characterized by piecemeal necrosis (interface hepatitis), and a rich plama cells infiltrate are highly distinctive aspects of AIH. On the other hand, if a lupus patient presents evidence of progressive non-autoimmune chronic hepatitis characterized by persistent severe inflammatory damage, we need to consider first other probable diagnosis of chronic liver injury, such as hepatitis B or C, or other autoimmune diseases overlapping with lupus. The discrimination is further complicated by the fact that liver histopathological features in patients with lupus hepatitis are miscellaneous and non-specific, similar to those in other liver diseases. It is therefore important, before diagnosing lupus hepatitis, to rigorously rule out other liver diseases, including drug-induced liver injury, alcohol liver disease, viral hepatitis (hepatitis A, B, C, D, E, Epstein-Barr virus or cytomegalovirus), and other autoimmune-associated liver diseases [AIH, PBC, primary sclerosing cholangitis (PSC)].

A recent study by Zheng et al based on this strict discrimination criteria reported a 9.3% lupus hepatitis incidence among 504 SLE patients evaluated. However, the prevalence reported in the literature is rather variable, with both lower [13,17,19] and higher [14,18,20] rate values.

Zheng et al also reported that the prevalence of lupus hepatitis in patients with active SLE was higher than those with inactive SLE (11.8% vs 3.2%). The patients with lupus hepatitis mostly showed mild to moderate elevations of serum transaminase levels, though 6 patients had jaundice as the predominant feature. ALP and Gamma

### Table 2 Laboratory abnormalities in the different hepatic manifestations associated with systemic lupus erythematosus

<table>
<thead>
<tr>
<th>Hepatic alteration</th>
<th>Laboratory abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic steatosis</td>
<td>GGT, ALT/AST</td>
</tr>
<tr>
<td>Viral hepatitis</td>
<td>ALT, AST, HCV, cryoglobulinemia</td>
</tr>
<tr>
<td>Toxic hepatitis</td>
<td>ALP, GGT, AST/ALT, bilirubin</td>
</tr>
<tr>
<td>Nodular regenerative hyperplasia</td>
<td>ALT, AST, thrombocytopenia</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
<td>ALP, GGT, AMA</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td>ANA, ASMA, gammaglobulin</td>
</tr>
<tr>
<td>Hepatic venous thrombosis</td>
<td>Antiphospholipic antibodies</td>
</tr>
<tr>
<td>Lupus hepatitis</td>
<td>Anti-ribosomal P autoantibodies</td>
</tr>
</tbody>
</table>

AMA: Antimitochondrial antibody; ANA: Antinuclear antibody; ASMA: Antismooth muscle antibody; GGT: Gamma glutamil transferase; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase.

[1,2,14,15]
glutamyl transferase elevations were far less frequent. Only 12.8% had liver injury-related clinical manifestations. Lupus hepatitis responds well to moderate to high doses of corticosteroids[19].

In patients suspected to have lupus hepatitis, it has been often reported a correlation between hepatic enzymes abnormalities and autoantibodies to ribosomal P proteins (anti-ribosomal P), a highly specific marker for SLE[19,21,22]. Indeed, several reports suggest that SLE-related hepatitis may be associated with, or even caused by this autoantibody.

Anti-ribosomal P occurs in 12%-16% of patients with lupus[21-24], although this proportion increased to 30% when more sensitive methods were employed [enzyme-linked immunosorbent assay (ELISA) based upon the combination of different ribosomal-P antigens], with Caucasian ethnicity having lower values[25]. The proportion of serum anti-ribosomal P occurrence raised to 44% among SLE patients with liver dysfunction and, from them, 70% had SLE-associated hepatitis, a far higher value as compared with SLE patients suffering from other hepatic alterations, such as fatty liver (29%), drug-induced hepatitis (17%), or SLE-AIH overlap syndrome (20%)[26]. Furthermore, Koren et al[27] reported the development of chronic active hepatitis in a patient with SLE followed several months later by the appearance of high serum levels of anti-ribosomal P antibodies, and suggested a possible causal relationship. As for the mechanism explaining this causal relationship, anti-ribosomal P positive sera from SLE patients were found to react strongly “in vitro” with a polypeptide antigenically related to a 38 kD ribosomal P0 protein present on the plasma membrane of hepatoma cells[28], thus further strengthening the possibility that anti-ribosomal P antibodies could be directly detrimental in lupus patients by inducing hepatocellular lysis, and further transaminase release. Finally, anti-ribosomal P antibodies up-regulate the expression of proinflammatory cytokines by peripheral monocytes in SLE, which may be a contributing factor for hepatitis development[29].

Given that auto-antibodies directed against eukaryotic P proteins are highly specific to SLE, they can be used as diagnostic markers of the disease. However, there is no standard methodology for its detection and titration in clinical practice. The plasma titers of this antibody often fluctuate in relation to lupus activity, and were formerly associated with neuropsychiatric kidney and liver failure[52,29].

Several isolated cases have been reported of association of anti-ribosomal P antibody occurrence with hepatitis, and also with kidney failure[27,30]. However, it was Arnett et al[31] the first to report this association in a cohort study in 1995. They found lupus-related hepatitis in 3% of 131 lupus patients in a retrospective study that analyzed the hepatic manifestations of SLE. The clinical outcome for these patients was variable, from a minimum, subclinical increase of transaminases to acute hepatitis and overt liver failure. Unfortunately, histological studies were not carried out in this study to correlate the degree of liver injury associated with lupus hepatitis and the levels of anti-ribosomal P antibodies.

Although these lines of evidence link anti-ribosomal P antibodies to liver damage in SLE patients, the association is still highly controversial. For example, lack of a clear association between lupus hepatitis and anti-ribosomal P levels was reported in a recently published retrospective study of 73 patients with SLE, where 12 of them (16%) were reported to have lupus hepatitis. In this group, 6 patients had a concurrent liver involvement with the diagnosis of SLE, and it occurred later during an exacerbation of the disease in the remaining 5 patients[32].

Clinical manifestations were as follows: hepatomegaly (n = 4), jaundice (n = 4), abdominal pain (n = 3), ascitis (n = 2), portal hypertension (n = 1), and hepatic failure with encephalopathy (n = 1). Despite elevated liver enzymes were noted in 11 cases and cholestasis in 8 ones, the presence of anti-ribosomal P antibodies was observed only in one case, and therefore an association between lupus hepatitis and any kind of specific antibody could not be documented. Liver biopsy in 5 patients showed chronic active hepatitis in 3 cases, chronic hepatic granulomas in 1 case, and nonspecific inflammation in another one. Although the authors showed clear evidence of immunosuppressive therapy response in most patients, liver biopsy was performed in less than half of them, and their description was not detailed enough to clearly differentiate lupus hepatitis from AIH.

In part, disagreements on the association between anti-ribosomal P antibody and lupus hepatitis can be explained by different features of the studied populations (e.g., ethnicity), environmental factors affecting autoantigen expression, and distinct degrees of sensitivity/specificity of the methods used to detect anti-ribosomal P antibodies. Usually, associations between anti-ribosomal P antibody levels and hepatitis were investigated by using well-standardized, or even “in-house” immunological methods[33,34]. Unfortunately, large cohort studies where lupus hepatitis or other SLE hepatic manifestations have been reliably documented, and where well-standardized, high sensitivity/specificity immunological methods are employed to detect anti-ribosomal P antibodies (e.g., those using a mixture the ribosomal P antigens P0, P1, and P3), are lacking, and we eagerly await them to confirm or deny the existence of this association.

To complicate the picture further, Calich et al[35] reported recently the presence of anti-ribosomal P antibodies in patients having AIH not associated with lupus (9.7%; 9/93), and suggested that this antibody predicts worse prognosis of the disease, with follow-up data showing higher prevalence of cirrhosis in anti-ribosomal P antibody-positive AIH patients (100%, 7/7). This finding suggests that anti-ribosomal P antibodies can be involved in the pathogenesis of other hepatic autoimmune diseases, apart from lupus hepatitis. The debate is still open, and it is apparent that we need more data to support the role and impact of anti-ribosomal P antibodies in both SLE and AIH pathogenesis.
Overlap of SLE with autoimmune liver diseases (overlap syndromes)

The existence of overlap syndromes linking SLE with other autoimmune liver diseases is matter of controversies since, again, the data in the literature are scarce.

According to the so-called “theory of the mosaic of autoimmunity”[32], each of these associations may represent a particular variant of a major underlying autoimmune disease, which can show up under the form of multiple autoimmune liver diseases coexisting in the same patient. Other good examples of such variants are more typical hepatic overlap syndromes, such as AIH-PBC and AIH-PSC[33].

Although AIH or PBC are rare among SLE patients taken as a whole[34], the co-existence of SLE with either of these liver diseases is not uncommon among the subgroup of SLE patients with liver enzyme abnormalities. Chowdhary et al[31] reported a strong association between SLE and autoimmune liver disease. They found that 8 out of 40 SLE patients (20%) were AIH carriers, while 6 (15%) showed evidence of PBC.

In another study by Efe et al[36], 36 SLE patients out of 147 (25%) had liver enzyme abnormalities, and 7 of them (4.7%) had SLE associated with another autoimmune liver disease. The rate rose to 19.4% when the subset of SLE patients having HLTs altered was considered and, from them, 72.3% fulfilled the criteria for AIH proposed by the International Autoimmune Hepatitis Group. The therapy with ursodeoxycholic acid, prednisone, immunosuppressive thiopurine analogs, or a combination of them, was successful in these patients.

SLE-AIH overlap syndrome

There have been very few reported cases of AIH associated with SLE. It is therefore apparent that AIH and SLE overlap syndrome is a rare condition, although its exact incidence is unclear.

Oka et al[39] reported 5 (3%) patients with AIH in an analysis of 162 cases of SLE meeting the ACR criteria. Similar findings were documented by Tamai et al[33], who found 10% of AIH in a series of 21 SLE cases.

There is evidence in the literature suggesting that SLE and AIH are different diseases, even when clinical, biochemical and serological characteristics may show overlapping features, such as the presence of polyarthritis, hypergammaglobulinemia, and positive ANA, ASMA and anti-ribonucleoprotein[40]. In these cases, liver histology is the decisive tool to define diagnosis. The presence of cirrhosis or perportal hepatitis associated with lymphocytes and plasma cells, presence of fibrosis in the portal areas and, eventually, cirrhosis[39,43]. In this context, positivity for anti-Sm antibodies, which are highly specific though relatively insensitive to SLE, helps to confirm SLE-AIH overlapping. In addition, presence of antibodies to double-stranded (ds) DNA, another hallmark of SLE, were found to be associated with poorer immediate response to corticosteroid treatment in AIH[43].

SLE-PBC overlap syndrome

PBC is also an autoimmune liver disease, and overlapping with PBC is likely to some extent. However, the co-existence of PBC and SLE is the subject of few reports in the literature, mostly based upon single case reports[38,43]. A large-scale study reported that, among 1032 PBC patients, 28 (0.30%) had also SLE[44]. Interestingly, anti-dsDNA and anti-ribosomal-P antibodies, two serological markers of SLE, were detected in 22% and 5%, respectively, of “pure” PBC patients[45].

SLE-PBC association has been documented mainly in patients with arthritis, polyserositis, and high titers of anti-native DNA and anti-mitochondrial antibodies (AMAs), two pathognomonic signs of SLE and PBC, respectively. Again, PBC can appear in a pre-existing lupus as an expression of an immunological disorder that has not been totally clarified. Osteopontin, a soluble ligand with pleomorphic immunologic activities that plays an important role in inflammation and immunity, may be a link. Osteopontin was reported to be highly expressed in the murphy roths large/lpr mouse[46], a well recognized model of SLE, and it is involved as a chemoattractant cytokine in the recruitment of macrophages and T lymphocytes in the liver granulomas in PBC[47]. Interestingly, Han et al[48], in a large cohort of 1141 SLE patients, confirmed the association between osteopontin and SLE.

Finally, AIH-PBC overlap syndrome has been reported to occur in 2.8% of SLE patients, suggesting the association of not only two but even three autoimmune diseases (SLE-AIH-PBC overlap syndrome)[49]. Furthermore, anti-dsDNA antibodies, which are known to be strongly associated with SLE, were detected in 60% of AIH-PBC patients, or 56% of patients with AIH-PBC overlap syndrome.

SLE-PSC overlap syndrome?

Evidence for SLE-PSC overlap syndrome is limited at best, and only based upon few case reports[50-52]. Whether this clinical association indicates that some immune disorders are common to the two autoimmune diseases or whether they were casual associations remains to be ascertained.

Association of SLE with non-autoimmune liver diseases (comorbidity)

SLE patients often present comorbidity with a number of non-autoimmune liver diseases. In many cases, the prevalence of the concomitant hepatopathy is higher when associated with SLE than alone, indicating either increased susceptibility to the concomitant disease trig-
gated by SLE or vice versa.

**Association of SLE with hepatitis C**

Autoimmunity and viral infections are closely associated fields, and viruses have been proposed as a likely etiological, contributing or even triggering factor of systemic autoimmune diseases[56]. This holds true also for SLE, since some hypotheses have identified viruses as potential agents that trigger SLE, with a close relationship to the pathogenic mechanism of damage[87].

Very little association has been found between SLE and patients infected with HCV. Most reports linking the two diseases refer to the presence in these patients of skin lesions, anti-DNA antibodies, hypocomplementemia and cryoglobulinemia[57].

In a study of 134 patients carrying SLE, the presence of anti-HCV antibodies (ELISA) was observed in 18 patients (13%), while the prevalence among voluntary blood donors in a large number of countries ranges from 0.5% to 2%, only. Active infection by HCV was confirmed in 15 (11%) of the patients with positive ELISA HCV[58]. Similar results were obtained in other study where HCV was detected in 4 out of 40 SLE patients (10%), whereas prevalence among voluntary blood donors was only of 0.13%[58]. Steroid therapy in these patients did not seem to alter the HCV course[69]. Whether this reflects a true higher HCV prevalence associated to SLE or it is a mere consequence of the multiple admissions and blood transfusions that these patients are subjected remains to be defined. Large-scale studies avoiding these potential bias are awaited.

It should be on the other hand acknowledged that HCV chronic infection is associated with different biochemical and histological manifestations of autoimmunity that, in certain cases, can mimic SLE[59]. Different types of non-organ-specific autoantibodies can be detected in chronic hepatitis C (e.g., anti-soluble liver antigen, ANA, AMT, rheumatoid factor) and, less frequently, it is associated with low anti-DNA titers; for example, about 20% with hepatitis C patients are ANA positive[61]. In addition, chronic hepatitis C can occur with cryoglobulinemia, which can lead to a wrong SLE diagnosis, due to the simultaneous occurrence of ANA, dermato logical and renal lesions and plaquetopenia; this is why, in patients suspected to have SLE, HCV infection must be excluded using routine anti-HCV serology and, HCV-RNA tests. Several factors lead to the production of autoantibodies in HCV patients, including leakage of intracellular components due to the persistent destruction of infected cells[62], the molecular mimicry between HCV and autoantigens[62], and the functional abnormalities of infected B lymphocytes, with production of excessive autoantibodies and cryoglobulins[60].

Fukuyama et al[68] reported for the first time in the literature the development of an SLE profile after interferon α-2 therapy. There are over 10 currently published cases that link the use of interferon to treat hepatitis C with the appearance of SLE associated with different levels of severity, including one patient with a serious lupus cardiomyopathy that threatened his/her life.

Although chronic infection with HCV can induce clinical and serological changes that can be confused with an autoimmune disease (arthritis, nephropathy, and cytopenias), the appearance of malar rash, discoid lesion, photosensitivity, neurological damage, high titers of ANA or anti-DNA antibodies, and anti-Sm antibody occurrence usually constitute sufficient evidence to diagnose SLE[7].

The clinician must consider three situations in the context of a HCV antibody in a patient with SLE, namely: (1) it may be a false positive HCV ELISA test due to the high levels of autoantibodies that are frequently presented in SLE patients; (2) could be true association between SLE and hepatitis C; and (3) HCV can trigger the occurrence of low levels of ANA and/or anti-DNA, associated with cryoglobulinemia, without typical skin changes[69].

One common complication of SLE patients is the so called “lupus nephritis”, and HCV may play a role. Few cases of lupus nephritis coexisting with HCV infection have been described[63,68]. Although speculative, it is likely that the altered immune response in SLE facilitates HCV infection, and vice versa, that different autoantibodies associated with HCV infection facilitate the development of lupus nephritis due to formation of immune complex deposits in the kidneys. The increase in serum B-lymphocyte activating factor levels in chronic HCV patients with infection and SLE may be a contributing factor, by reinforcing B-cell activation and autoantibody production[7].

**Association of SLE with hypercoagulagulation state-related liver lesions**

SLE patients have a high potential to develop thrombembolic disorders that can impact on hepatic circulation[68]. The frequent presence of anti-phospholipid antibodies among these patients can include thrombotic manifestations in different territories of the splanchic vasculature, both in arterial and venous areas (thrombosis of the hepatic artery, portal thrombosis, and Budd-Chiari syndrome)[69]. Portal hypertension profiles and esophageal varices have also been reported in several cases as secondary events linked to thrombosis of the portal vein, triggered by the presence of anti-cardiolipin antibodies[70].

Regenerative nodular hyperplasia (RNH), which follows hepatic vein thrombosis and hepatic circulation disorders, has also been reported in association with SLE (Figure 1)[70]. The pathogenesis of RNH complicating SLE is believed to be related to vasculitis of intrahepatic arteries, leading to secondary portal venous obliteration and thrombosis of the adjacent portal veins[8]. Alternatively, occlusion of intrahepatic small vessels may result from coagulopathy in patients with associated anti phospholipid syndrome[9]. It has been suggested that anti phospholipid antibodies play a pathogenic veno-occlusive role in the pathogenesis of RNH[51].

One of the most attractive theories regarding RNH
Regenerative nodular hyperplasia (RNH) is a benign liver lesion characterized by the presence of multiple hepatic nodules ranging from several centimeters. It is often associated with hematological diseases and various conditions that typically present systemic impairment (rheumatoid arthritis, CREST syndrome, Felty’s syndrome). Another theory suggests that the association between RNH and anti-phospholipid antibodies is due to the cellular regeneration process that begins in the liver to maintain its functional capacity after the ischemic injury induced by these antibodies in the hepatic microcirculation.

RNH should be suspected in any patient with both SLE and portal hypertension in the absence of cirrhosis. The diagnosis can be established after a liver biopsy. Due to the large size of the regenerative nodes, there is a chance for the needle to be positioned in an area with no histological damage, which accounts for sampling error. When RNH is to be diagnosed, laparoscopic wedge biopsy is a safe and efficient way to obtain enough tissue to preserve the hepatic architecture required for analysis, avoiding in turn the morbidity associated with an unnecessary open resection.

Hepatic imaging of RNH shows several additional findings, including focal nodular hyperplasia (FNH), hepatocellular adenoma, regenerative nodules, and liver metastatic disease. Computed tomography can show normal liver, numerous small nodules, or larger coalesced nodules spanning several centimeters. On nuclear medicine imaging, these lesions may take up sulfur colloid, but will remain iso- or hypodense in both arterial and portal venous phases; this helps to distinguish RNH from FNH. The use of magnetic resonance imaging (MRI) to enhance diagnostic accuracy is still controversial. RNH lesions appear hyperintense on T1-weighted imaging and iso- or hypointense on T2 images (Figure 1). However, the sensitivity and specificity are variable, according to a recent report.

RNH may be differentiated from large regenerative nodules (LRN) by either tomography or MRI. LRN can have a distinct presentation, and very often results in enhancing liver nodules, whereas RNH usually does not. The spontaneous rupture of the liver has also been reported in patients with SLE as a serious consequence related to the occurrence of a large area of infarction, due to a thrombotic phenomena of the hepatic artery.

Focal disturbance of the hepatic blood supply associated with lupus might also facilitates the hyperplastic development of benign lesions in the liver, such as FNH and hemangiomas. In a recent study analyzing a cohort of 35 SLE patients, FNH was observed at higher rates (5.7%) than in the normal population (0.6%-3.0%), and the same holds true for hemangiomas (54.2% vs 0.4%-20% in the general adult population). Whereas FNH is thought to be part of an abnormal adaptive regenerative response of the liver parenchyma to local hemodynamic disturbances, hemangioma formation may be also favored by an increase of angiogenic factors whose circulating levels are increased in SLE patients, such as estrogens, vascular endothelial growth factor, and interleukin-18. Confirmation of an increased incidence of these kinds of hepatic benign lesions in SLE patients awaits large-scale studies.

Association of SLE with porphyria cutanea tarda
The association of SLE with porphyria cutanea tarda (PCT), the most frequent type of porphyria, is rare, and data defining whether this concomitance is pure coincidence or true association are still lacking.

Common features in both diseases may be a confusing factor. SLE is similar to PCT regarding photosensitivity, but the presence of blisters involving crusts and miliae in sun-exposed areas of PCT patients, which is characteristic of PCT but rare in SLE (< 5% of the cases), can help to differentiate both diseases.

Coexistence of PCT is usually associated with an-
timal drugs for treating lupus (e.g., chloroquine, hydroxychloroquine), and the regular use of these drugs in SLE patients should be considered a risk for PCT. This usually represents a diagnostic problem, given the frequent association of PCT with a long list of drugs apart from antimalarial agents, which makes the diagnosis of the cause even more complicated. The risk associated with antimalarial drugs is dose-dependent; this is why several authors have contraindicated the daily intake of these drugs for SLE due to the risk of massive porphyria cutanea tarda, which is often associated with fever, nausea and hepatocellular injury, leading eventually to hepatic necrosis.

**Association of SLE with drug-induced hepatotoxicity**

Patients with SLE seem to have a relatively high rate of drug-induced hepatotoxicity (Table 3). For example, Huang et al. reported 35 cases of drug-induced hepatotoxicity among 1533 SLE patients reviewed. In another study by Takahashi et al., liver damage could be ascribed to drug-induced liver injury in 31% from a total of 123 SLE patients with overt liver dysfunction.

At the moment, it is impossible to know with certainty whether this high incidence is due to the chronic use, at relatively high doses, of different drugs commonly prescribed to treat this disease, or whether there is any kind of particular susceptibility that makes these patients prone to drug-induced hepatotoxicity. Of note, SLE patients have been shown to have elevated levels of systemic oxidative stress, which well correlated with liver enzyme elevations. This relationship can be tentatively explained by drug-induced oxidative stress in the liver of these patients, with consequent liver injury. The elevated pro-oxidant liver status associated with a pro-inflammatory conditions like SLE may also make the organ prone to develop hepatotoxicity by drugs exerting detrimental effects via oxidative mechanisms. Indeed, several drugs used in autoimmune disease may themselves be converted into free radicals “in vitro”, thus aggravating oxidative damage. Controlled, comparative studies on differential susceptibility to the same drug in patients with SLE and other autoimmune disease (e.g., rheumatoid arthritis) are lacking, but they would be useful to establish whether SLE is indeed a peculiar prone condition for drug-induced liver injury.

Around 80% of SLE patients are treated with analgesic and NSAIDs, prescribed for febrile syndrome, arthralgia/arthritis, serositis and/or cephalalgia. Hepatitis, fulminant hepatic failure, cholestasis, and mixed damage were reported to be caused by these compounds.

Lupus patients usually present a higher rate of NSAID-related complications than SLE-negative subjects. The most common complications are increased transaminase levels, skin rashes triggered by sun, increased retention of body fluids with arterial hypertension, gastri-c ulcers, and aseptic meningitis. NSAIDs should not be indicated over the counter in SLE, and prescription must always be accompanied by recommendations related to strict clinical and laboratory vigilance.

For many years, aspirin was the most common drug associated with SLE-related liver damage. Increments of ALT, AST and ALP have been reported in up to 25% of the SLE patients consuming high doses of aspirin (> 2 g/d).

In the early 70’s, the first publications appeared identifying aspirin as responsible for the hepatic damage in SLE patients. It was not however until 1981 that Zimmerman, in a review focused on this issue, showed with certainty that aspirin generates both acute and chronic dose-dependent liver damage.

The onset of aspirin-induced liver disease is marked by the appearance of anorexia, nausea and non-specific pain in the upper abdomen. The patient usually does not present jaundice, and ALT and AST values are usually not more than 10 times ULN values. It is very common that AST levels are higher than ALT, and that these alterations present jaundice, and ALT and AST values are usually not more than 10 times ULN values. It is very common that AST levels are higher than ALT, and that these alterations present jaundice, and ALT and AST values are usually not more than 10 times ULN values. It is very common that AST levels are higher than ALT, and that these alterations present jaundice, and ALT and AST values are usually not more than 10 times ULN values. It is very common that AST levels are higher than ALT, and that these alterations present jaundice, and ALT and AST values are usually not more than 10 times ULN values. It is very common that AST levels are higher than ALT, and that these alterations

### Table 3: Hepatotoxicity induced by drugs used in lupus treatment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Liver injury and clinical significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticosteroids</td>
<td>Hepatomegally</td>
</tr>
<tr>
<td></td>
<td>Fatty liver</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>Asymptomatic ALT increase</td>
</tr>
<tr>
<td></td>
<td>Hepatocellular, cholestatic, or mixed injury (resolve with withdrawal)</td>
</tr>
<tr>
<td>ASA</td>
<td>Acute and chronic hepatocellular injury (resolve with withdrawal)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Asymptomatic ALT increase at high doses</td>
</tr>
<tr>
<td></td>
<td>Estenosis, fibrosis, or cirrhosis</td>
</tr>
<tr>
<td>Anti-malarial drugs</td>
<td>Rare hepatotoxic effects</td>
</tr>
<tr>
<td></td>
<td>Porphyria cutanea tarda</td>
</tr>
<tr>
<td>Azatioprine</td>
<td>Cholestasis, peliosis, SOS, RNH</td>
</tr>
<tr>
<td>Thioguanine</td>
<td>SOS, RNL, portal hypertension</td>
</tr>
<tr>
<td>Ciclophosphamide</td>
<td>Rare case reports at conventional doses</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>Asymptomatic ALT increase at high doses (resolve with dose reduction)</td>
</tr>
<tr>
<td>Rituximab</td>
<td>No liver reactions have been reported</td>
</tr>
<tr>
<td>Belimumab</td>
<td>No liver reactions have been reported</td>
</tr>
</tbody>
</table>

1 Anti-malarial drugs: chloroquine, hydroxychloroquine. ALT: Alanine aminotransferase; NSAIDs: Non-steroidal antinflammatory drugs; ASA: Acetylsalicilic acid; RNH: Nodular regenerative hyperplasia; SOS: Sinusoidal obstruction syndrome.
use to gain or maintain remission in SLE. Hepatotoxicity induced by thiopurine analogues occurs very often with increase in serum transaminase levels. It is associated generally with not severe liver injury, which responds to dose reduction in most patients. RNH is also a very rare but potentially severe complication of thiopurine-based therapies. It is often asymptomatic, and neither biochemical nor molecular markers are indicative of RNH. The suspicion should arise when there are clinical symptoms of portal hypertension, increments of transaminase levels, or thrombocytopenia. A liver biopsy is essential in this case to confirm diagnosis\[107\].

A recent review by Musumba\[108\] reports that inflammatory bowel disease patients treated with AZA have a cumulative incidence of RNH at 5 and 10 years of 0.6% and 1.3%, respectively, whereas those treated with high TG doses (> 40 mg/d) have an incidence of RNH of up to 62%; this rate is even higher in patients with elevated liver enzymes and/or thrombocytopenia, as compared with those lacking these abnormalities (76% vs 33%).

Methotrexate (MTX) is currently the first-line therapy for early and chronic rheumatic and psoriatic arthritis, but it is also indicated to symptomatic patients with SLE\[109\]. The recognition of risk of chronic liver damage with MTX has prompted the need for intensive biochemical monitoring from several decades ago onwards. The frequency of hepatotoxicity varies widely according to differences in sampling, definitions of damage, dose regimens, and presence of other risk factors\[110\]. Although one study showed transaminase elevations higher than twice the upper limit of normal in 13% of patients\[111\], another report assessing 6000 patients receiving MTX, transaminase elevation was described in only 0.6% of patients\[112\]. Despite this wide difference, most studies concluded that prolonged use of low-dose MTX monotherapy (10 mg/wk for 2-15 years) has favorable long-term safety, and that the development of significant liver fibrosis and cirrhosis is very low\[113\]; rather, steatosis was the main finding when biopsies were carried out for surveillance dictated by cumulative MTX dose (Figure 2)\[114\]. Due to this disparity, Society’s guidelines differ on how patients on MTX should be monitored to prevent MTX-induced liver fibrosis\[115,116\].

Although liver biopsy is still suggested in these patients in case of persistent elevation of transaminase after drug discontinuation, and for ruling out other potential cause of chronic liver disease, there is robust evidence that Fibroscan Elastography may become in a near future the gold standard for fibrosis investigation in patients treated with MTX\[117,118\]. Most studies concluded that MTX therapy is safe, and that Fibroscan is useful for monitoring liver fibrosis in patients treated with this drug. Conclusions drawn from several studies indicate that severe liver fibrosis is a rare event in patients treated with MTX, and that it is probably unrelated to the dose. A recent work also studied the accuracy and feasibility of Fibroscan and Fibrotest to detect MTX-induced liver fibrosis in 24 psoriasis patients\[119\]. The results obtained using Fibroscan and Fibrotest were compared with those obtained by liver histology. In this cohort, Fibrotest accurately predicted the presence of liver fibrosis, while Fibroscan accurately predicted the absence of liver fibrosis in MTX users. These findings suggest that a combination of approaches should prospectively be evaluated in monitoring and detecting significant MTX-induced liver fibrosis.

An association between MTX-induced toxicity and genetic polymorphism was suggested. Fisher et al\[120\] conducted a meta-analysis of published studies including 1400 patients for association of the C677T polymorphism of the gene encoding methylene tetrahydrofolate reductase (MTHFR), and over 660 patients for the A1298C variant. They observed that the former but not the latter MTHFR gene variant was significantly related to MTX toxicity, including hepatotoxicity (OR = 1.71; CI: 1.32-2.21, \(P < 0.001\)). Despite results for MTHFR...
Liver abnormalities is very common among patients with SLE, especially if they are assessed from the biochemical point of view. It is generally asymptomatic, and frequently associated with steatosis, reactive unspecific changes and drug-related hepatotoxicity. Severe and progressive liver injury may occur, and even more often in the context of a coexisting primary liver disease or during pharmacotherapy.

SLE by itself is not usually associated with aggressive liver disease, but with an often asymptomatic entity referred to as “lupus hepatitis”, which is characterized by a mild increase in serum transaminase levels. However, there are overlapping profiles with other autoimmune disease, such as AIH and PBC, related to chronic and aggressive damage, sometimes accompanied by changes in immunological liver tests that help to establish an accurate diagnosis. These overlap syndromes are thought to be variants of an underlying general autoimmune disease, which shows up in a variable arrangement of autoimmune disorders. An etiological role for anti-ribosomal P antibodies in triggering both lupus hepatitis and AIH has been proposed, but it remains uncertain and controversial.

SLE patients often present comorbidity with non-autoimmune liver diseases. They includes HCV, thrombotic events in the splanchic vasculature, PCT, and drug-induced hepatotoxicity, among others.

Hepatic circulation disorders may lead to adaptive parenchymal regenerative processes (e.g., RNH, FNH) or formation of hemangiomas. RNH must be ruled out in all lupus patients who present evidence of portal non-cirrhotic hypertension associated with hepatic pseudonodular images.

Drug-induced liver toxicity is also a common event in SLE, and may be ascribed to the chronic use, at high doses, of medicines used to control the autoimmune disorder (e.g., thiopurine analogues, anti-TNF-α agents, statins, minocycline, cyclophosphamide) or to mitigate SLE symptoms (e.g., NSAIDs, MTX). SLE is an oxidative-stress-prone condition, and the pro-oxidant effects of many of these drugs may be a causal factor.

Due to the relatively frequent multifaceted manifestations of liver diseases in SLE, with an often difficult differential diagnosis each others, an assessment of immunological, serological and virological markers should be systematically carried out in patients with elevated levels of liver enzymes. Testing for AMA, ASMA, and HCV is in some cases the only reliable method of diagnosis. These overlap syndromes are thought to be variants of an underlying general autoimmune disease, such as AIH and PBC, related to chronic and aggressive damage, sometimes accompanied by changes in immunological liver tests that help to establish an accurate diagnosis. These overlap syndromes are thought to be variants of an underlying general autoimmune disease, which shows up in a variable arrangement of autoimmune disorders. An etiological role for anti-ribosomal P antibodies in triggering both lupus hepatitis and AIH has been proposed, but it remains uncertain and controversial.

REFERENCES


**82 Banks** AT, Zimmerman HJ, Ishak KG, Carter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to
Bessone F et al. Liver disease in lupus


De Santis M, De Santis M, 401-413 [PMID: 12879991]


_P- Reviewers:_ Atta AM, Efe C, Vazquez-Del Mercado M

_S- Editor:_ Ji FF  _L- Editor:_ A  _E- Editor:_ Liu SQ